CN116234555A - 改良形式的曲美他嗪的改良释放制剂 - Google Patents

改良形式的曲美他嗪的改良释放制剂 Download PDF

Info

Publication number
CN116234555A
CN116234555A CN202180051890.7A CN202180051890A CN116234555A CN 116234555 A CN116234555 A CN 116234555A CN 202180051890 A CN202180051890 A CN 202180051890A CN 116234555 A CN116234555 A CN 116234555A
Authority
CN
China
Prior art keywords
imb
hours
trimetazidine
dose
hpmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051890.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·D·莱文
J·帕特尔
G·慕尼
S·赫比格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambria Pharmaceutical
Original Assignee
Ambria Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambria Pharmaceutical filed Critical Ambria Pharmaceutical
Publication of CN116234555A publication Critical patent/CN116234555A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180051890.7A 2020-06-30 2021-06-28 改良形式的曲美他嗪的改良释放制剂 Pending CN116234555A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063046117P 2020-06-30 2020-06-30
US202063046115P 2020-06-30 2020-06-30
US63/046,117 2020-06-30
US63/046,115 2020-06-30
US202163183299P 2021-05-03 2021-05-03
US202163183294P 2021-05-03 2021-05-03
US63/183,299 2021-05-03
US63/183,294 2021-05-03
PCT/US2021/039303 WO2022005926A1 (en) 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine

Publications (1)

Publication Number Publication Date
CN116234555A true CN116234555A (zh) 2023-06-06

Family

ID=79315460

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051890.7A Pending CN116234555A (zh) 2020-06-30 2021-06-28 改良形式的曲美他嗪的改良释放制剂

Country Status (8)

Country Link
EP (1) EP4171232A4 (https=)
JP (1) JP2023531802A (https=)
KR (1) KR20230028535A (https=)
CN (1) CN116234555A (https=)
AU (1) AU2021299197A1 (https=)
CA (1) CA3187827A1 (https=)
IL (1) IL299544A (https=)
WO (1) WO2022005926A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080139655A1 (en) * 2006-09-08 2008-06-12 Drugtech Corporation Sustained-release composition and method of use thereof
CN109833304A (zh) * 2017-11-27 2019-06-04 信越化学工业株式会社 固体制剂用组合物、固体制剂及其制备方法
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法
WO2020081361A1 (en) * 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
CN111093662A (zh) * 2017-06-20 2020-05-01 安布里亚制药公司 用于提高心脏代谢效率的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466371B (zh) * 2006-06-09 2011-10-05 施瓦茨制药有限公司 含非索罗定的稳定的药用组合物
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
NZ745921A (en) * 2016-03-09 2021-12-24 Nls 1 Pharma Ag A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080139655A1 (en) * 2006-09-08 2008-06-12 Drugtech Corporation Sustained-release composition and method of use thereof
CN111093662A (zh) * 2017-06-20 2020-05-01 安布里亚制药公司 用于提高心脏代谢效率的组合物和方法
CN109833304A (zh) * 2017-11-27 2019-06-04 信越化学工业株式会社 固体制剂用组合物、固体制剂及其制备方法
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法
WO2020081361A1 (en) * 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds

Also Published As

Publication number Publication date
EP4171232A1 (en) 2023-05-03
IL299544A (en) 2023-02-01
JP2023531802A (ja) 2023-07-25
CA3187827A1 (en) 2022-01-06
WO2022005926A1 (en) 2022-01-06
KR20230028535A (ko) 2023-02-28
AU2021299197A1 (en) 2023-02-02
EP4171232A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US12233088B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
US12048768B2 (en) Gastro-resistant controlled release oral dosage forms
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
US20230210845A1 (en) Dosing methods for treatment of cardiovascular conditions
CN116234555A (zh) 改良形式的曲美他嗪的改良释放制剂
US20210401833A1 (en) Modified release formulations of modified forms of trimetazidine
US20210401834A1 (en) Modified release formulations of modified forms of trimetazidine
JP2024540172A (ja) 心血管状態を処置するための方法および心臓の代謝効率を増大させる方法
RU2787632C2 (ru) Бис-холина тетратиомолибдат для лечения болезни вильсона
CA3084100C (en) Bis-choline tetrathiomolybdate for treating wilson disease
Tablets et al. Pr SANDOZ SAXAGLIPTIN
Agent KOMBOGLYZE®
Hydrochloride et al. PrMYLAN-PIOGLITAZONE
Agent PrVAN-Pioglitazone
CN107157987A (zh) 含氮的天然产物的医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination